BioCentury | Feb 28, 2020
Distillery Therapeutics

An antisense oligo inhibitor of miR-132 for heart failure

DISEASE CATEGORY: Cardiovascular INDICATION: Heart failure The miR-132 inhibitor CDR132L could treat heart failure. In pigs with post-myocardial infarction heart failure, CDR132L improved cardiac function, prevented end-systolic volume enlargement and reduced histologic evidence of interstitial...
BioCentury | Jan 11, 2019
Company News

U.K. firm licenses trial success prediction tool from Molecular Health

Daten Capital LLP (London, U.K.) received exclusive rights from Molecular Health (Heidelberg, Germany) to Molecular Health Predict (MH Predict), an AI-based tool to predict the outcome of clinical trials, for use in the financial industry....
BioCentury | Aug 23, 2018
Distillery Techniques

Assays and screens; imaging; drug properties

TECHNOLOGY: Cellular assays; fluorescence; drug-drug interactions A cell-based imaging method could identify targets that promote resistance to PARP inhibitors and identify synergistic combinations of PARP and other inhibitors. The method uses fluorescent microscopy in cancer...
BioCentury | Jul 28, 2016
Distillery Therapeutics

Therapeutics: MicroRNA-125b-5p (miR-125b-5p)

Hepatic disease INDICATION: Liver failure Patient sample, cell culture and mouse studies suggest miR-125b-5p could help treat acute liver failure caused by acetaminophen and other toxins. In liver tissue samples, miR-125b-5p levels were lower in...
BioCentury | Jun 16, 2016
Distillery Therapeutics

Therapeutics: Forkhead box A1 (FOXA1); FOXA2; FOXA3; GATA binding protein 4 (GATA4); HNF1 homeobox A (HNF1A); hepatocyte nuclear factor 4 α (HNF4A; TCF) FOXA3,

Hepatic disease INDICATION: Liver fibrosis Mouse studies suggest in vivo reprogramming of liver myofibroblasts into hepatocyte-like cells could help treat liver fibrosis. In a mouse model of the disease, in vivo transduction of myofibroblasts with...
BioCentury | Feb 25, 2016
Distillery Therapeutics

Therapeutics: Cardiac hypertrophy-associated transcript (CHAST)

Cardiovascular disease INDICATION: Heart failure Mouse studies suggest inhibiting the long non-coding RNA (lncRNA) CHAST could help treat heart failure. In mouse models of cardiac hypertrophy, CHAST levels were higher than in normal mice. In...
BioCentury | May 21, 2015
Distillery Therapeutics

Therapeutics: Dynamin (DMN)

Renal disease INDICATION: Renal Zebrafish and rodent studies suggest enhancing DMN oligomerization in podocytes could help treat chronic kidney disease (CKD). In zebrafish embryoys, morpholino-mediated knockdown of the homolog of human DMN decreased renal function...
BioCentury | Feb 9, 2015
Politics, Policy & Law

Margaret Hamburg reflects

BioCentury spoke with Margaret Hamburg last week after she announced her decision to resign as FDA commissioner at the end of March. Reflecting on almost six years in office, she highlighted efforts to enhance science...
BioCentury | Feb 5, 2015
Distillery Therapeutics

Therapeutics: Myeloid derived growth factor (MYDGF); vascular endothelial growth factor A (VEGF-A)

Cardiovascular disease INDICATION: Myocardial infarction (MI) In vitro and mouse studies suggest MYDGF could help treat MI. In neonatal rat ventricular myocytes, recombinant MYDGF protein secreted by bone marrow cells decreased ischemia and reperfusion injury-induced...
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Vitamin D receptor (VDR) In vitro and mouse studies suggest vitamin D analogs could help treat pancreatic cancer. VDR levels were higher in...
Items per page:
1 - 10 of 57